Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

Trial Profile

Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Inecalcitol (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms INIM study
  • Sponsors Hybrigenics
  • Most Recent Events

    • 12 May 2017 According to a Hybrigenics media release, the company presented encouraging initial results for inecalcitol in combination with oral imatinib in chronic myeloid leukaemia.
    • 22 Apr 2015 New trial record
    • 20 Apr 2015 This trial was initiated in January 2015, according to a Hybrigenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top